Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
20 hedge funds and large institutions have $3.9M invested in Petros Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.04% more ownership
Funds ownership: 0% → 0.04% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
+$1.45M |
| 2 |
Renaissance Technologies
New York
|
+$539K |
| 3 |
AFAS
Acorn Financial Advisory Services
Reston,
Virginia
|
+$236K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$233K |
| 5 |
PTP
Platform Technology Partners
New York
|
+$166K |
Top Sellers
PTPI Hedge Fund Activity: Q4 2020 in Review
20 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q4 2020, worth a combined $3.9M.
Buyers outnumbered sellers: 20 funds opened new PTPI positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NorthRock Partners, opening a new position worth an estimated $1.45M.
- 20 institutional investors held Petros Pharmaceuticals (PTPI) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $3.9M of Petros Pharmaceuticals stock for Q4 2020.
- 20 funds opened new Petros Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +20 holders.
- The largest Petros Pharmaceuticals buyer in Q4 2020 was NorthRock Partners, an estimated $1.45M added.
Based on aggregated 13F filings for Q4 2020.